BMO Capital on BioNTech (BNTX): 'Catalyst-Rich 2026 to Spotlight Differentiation of Onc Assets'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $143.00 price target on BioNTech (NASDAQ: BNTX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
